Nasdaq:GNPX
Genprex, Inc.
A clinical-stage oncology biotech firm advancing targeted therapies for prostate cancer patients with minimal current treatment options.
Key Metrics
Investment Thesis
Bull Case
Investors may consider GNPX for its potential to capture market share in the lucrative oncology space if GNP-1028 achieves regulatory approval and demonstrates superior clinical efficacy compared to existing prostate cancer treatments, offering substantial upside from a low current market capitalization.
Bear Case
The stock presents high risk due to a lack of revenue generation and a deepening retained earnings deficit of $154.8 million, requiring continuous equity financing that could lead to aggressive shareholder dilution if clinical milestones are not met in the near term.
About Genprex, Inc.
Genprex, Inc. (GNPX) is a biotechnology company focused on developing novel therapies for oncology, primarily targeting prostate cancer through its proprietary drug candidate GNP-1028. The company operates in the specialized pharmaceutical research and development sector, seeking to bring new treatment options to patients with limited therapeutic choices.
Analysis
Management Discussion
Financial performance indicates a substantial net loss of $21.1 million in 2024, driven by significant research and development expenditures totaling $10.5 million alongside general and administrative costs of $10.6 million. Despite receiving $12.0 million in financing cash flows during the period, the company's operating cash flow turned negative at -$17.1 million, resulting in a net decrease in cash reserves.
Industry Overview
The oncology biotechnology industry is characterized by high failure rates in late-stage clinical trials but offers massive potential rewards for successful drug candidates, particularly those addressing unmet medical needs like resistant prostate cancer where traditional chemotherapy and immunotherapies often fail.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $23.8M | $31.1M | $21.2M |
| Operating Income | $-23.8M | $-31.1M | $-21.2M |
| R&D | $11.5M | $17.6M | $10.5M |
| G&A | $12.3M | $13.4M | $10.6M |
| Stock-Based Comp | $4.7M | $5.4M | $3.3M |
| Depreciation | $25.6K | $15.0K | $6.7K |
| Amortization | — | — | $773.5K |
| Other OpEx | $25.6K | $15.0K | $6.7K |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | $90.1K | $215.1K | $63.6K |
| Pre-Tax Income | $-23.8M | $-31.1M | $-21.2M |
| Income Tax | $-90.1K | $0 | $2.6K |
| Continuing Ops | $-23.7M | $-31.1M | $-21.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-23.7M | $-30.9M | $-21.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-23.7M | $-30.9M | $-21.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $21.5M | $7.5M | $2.1M |
| Cash & Equivalents | — | $6.7M | $1.6M |
| Accounts Receivable | $34.9K | $0 | — |
| Prepaid Expenses | $484.2K | $794.1K | $475.8K |
| Other Current Assets | $21.0M | $0 | $0 |
| Long-Term Assets | $3.6M | $3.1M | $2.0M |
| PP&E (Net) | $23.0K | $7.9K | $0 |
| Intangibles | $702.1K | $773.5K | $0 |
| Other LT Assets | $2.9M | $2.4M | $2.0M |
| Total Assets | $25.1M | $10.7M | $4.1M |
| Current Liabilities | $2.8M | $3.3M | $2.5M |
| Long-Term Liabilities | $0 | $0 | $0 |
| Total Liabilities | $2.8M | $3.3M | $2.5M |
| Shareholders' Equity | $22.3M | $7.4M | $1.6M |
| Paid-In Capital | $125.1M | $141.1M | $156.4M |
| Retained Earnings | $-102.8M | $-133.7M | $-154.8M |
| Total L&E | $25.1M | $10.7M | $4.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-23.7M | $-30.9M | $-21.1M |
| Non-Cash Adjustments | $4.7M | $5.4M | $5.0M |
| Working Capital Changes | $1.2M | $707.2K | $-1.1M |
| Cash from Operations | $-17.8M | $-24.7M | $-17.1M |
| Capital Expenditures | $0 | — | — |
| Cash from Investing | $97.7K | $-71.2K | $1.2K |
| Cash from Financing | $6.4K | $10.6M | $12.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-17.7M | $-14.2M | $-5.1M |
| Beginning Cash | $38.6M | $21.0M | $6.7M |
| Ending Cash | $21.0M | $6.7M | $1.6M |
Frequently Asked Questions
How does Genprex, Inc. make money?
The company's operations are centered on its core drug candidate GNP-1028 and related research activities, currently generating no revenue from product sales as it remains in the pre-revenue development phase typical of early-stage biotechnology firms.
What are the main risks for GNPX?
The company faces significant cash burn of approximately $21.1 million annually without current revenue streams, reliance on successful clinical trial outcomes for GNP-1028 approval, potential dilution from future equity issuances to fund operations, and the inherent high risk associated with pre-commercial biotechnology assets.
What is GNPX's competitive advantage?
Genprex possesses a proprietary intellectual property portfolio focused on nucleic acid therapeutics for oncology, operates with a lean capital structure relative to peers due to recent financing rounds, and targets an underserved market segment in prostate cancer treatment where standard therapies have diminishing efficacy.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.